Last Updated: August 10, 2026

Claims for Patent: 6,974,833

✉ Email this page to a colleague

Summary for Patent: 6,974,833

Title:	Synergistic compositions comprising ascobate and lysine for states related to extra cellular matrix degeneration
Abstract:	Methods for the treatment of diseases or pathological states related to the degradation of the extracellular matrix, such as degenerative diseases atheriosclerosis, cancer, infection or other inflammatory diseases are disclosed, comprising administering compositions of lysine, proline, ascorbate, and their derivatives and synthetic analogues and vitamins, pro-vitamins and trace elements.
Inventor(s):	Rath; Matthias (Cupertino, CA)
Assignee:
Application Number:	09/761,395
Patent Claims:	1. A method for treatment of a collagenase-linked degenerative disease in a mammal in need thereof comprising administering to the mammal a therapeutic effective amount of a composition comprising: i) at least one collagen synthesis activator selected from the group consisting of ascorbyl .epsilon.-aminocaproate, and ascorbyl aminomethylcyclohexane carboxylic acid; ii) at least one fibrinolytic inhibitor selected from the group consisting of .epsilon.-aminocaproic acid, tranexamic acid, p-aminomethylbenzoic acid, p-benzylamine sulfuric acid, .alpha.-N-acetyl-lysine-methyl ester, cis/trans-4-aminomethylcyclohexane carboxylic acid, trans-4-aminomethycyclohexane carboxylic acid, 4-aminomethyl-bicyclo-2,2.2-octane carboxylic acid, natural lysine and proline; iii) at least one anti-oxidant selected from the group consisting of tocopherol, carotene and N-acetyl cysteine, selenium, and probucol; and iv) a pharmaceutically acceptable carrier, wherein the i)-iv) ingredients of the composition function to inhibit extracellular matrix degradation and stimulate collagen synthesis so as to treat the collagenase-linked degenerative disease. 2. The method according to claim 1, wherein the composition is administered orally or parenterally.

Details for Patent 6,974,833

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	June 04, 1965	6,974,833	2021-01-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.